Attorneys, Insurers Disagree With Manufacturers On Need For Clinical Evidence For MCIT Coverage
CMS says in its MCIT proposal that there’s no obligation for clinical studies, but AHIP is concerned about “clinical appropriateness” of devices
Executive Summary
Both insurance group AHIP and the MedPAC group of Medicare advisors are insisting on CMS reimbursement for medical devices only supported by clinical trials. Industry attorneys weigh in.
You may also be interested in...
Industry Comments Show Support For MCIT Proposed Rule – With Reservations
Industry groups were cool to parts of the CMS’s proposed Medicare Coverage of Innovative Technology (MCIT) rule dealing with commercial insurance coverage, as well as definitions used in the proposal.
Game-Changer? CMS Proposes Rule To Cover Breakthrough Devices On Provisional Basis
The long-awaited proposed rule from the US Medicare agency would allow breakthrough products approved by the FDA to get reimbursed, while manufacturers continue to collect clinical and real-world data.
10 Predictions On How Health Policy Could Change Under A Biden Presidency
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: